We sat down with Haran Maheson, Vice President & Head of Oncology at Daiichi Sankyo UK, to find out more about the company’s rapid growth, their vision to transform cancer care in the UK ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking ... it makes insulin brand Lantus, the company said on Thursday.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effe ...

Prior to this, he served as chief operating officer of the company. In a press release, Okuzawa said, “I am deeply honored to be the next CEO of Daiichi Sankyo and will follow Sunao Manabe’s ...

TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price target of Yen7,600.00. Stephen Barker has given his Buy ...

In a report released yesterday, Seiji Wakao from J.P. Morgan maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report), with ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...